RelA/NF-κB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells

Cell Death and Differentiation

Volumn 15, Issue 2, 2008, Pages 354-363

  Cianfrocca, R ^a   Muscolini, M ^a   Marzano, V ^a   Annibaldi, A ^a   Marinari, B ^b   Levrero, M ^a,c   Costanzo, A ^b,c   Tuosto, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Rome Oncogenomic Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P300; PROTEIN P53; PROTEIN P73; RNA POLYMERASE II; TRANSCRIPTION FACTOR RELA; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PROTEIN BCL X; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IRRADIATION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; CD4+ T LYMPHOCYTE; CELL CULTURE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; PHYSIOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE;

ANTIGENS, CD28; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DNA-BINDING PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; JURKAT CELLS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA POLYMERASE II; T-LYMPHOCYTES; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 38049138751     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402264     Document Type: Article

References (36)

1. Opferman JT, Korsemeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003; 5: 410-415.
2. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-372.
3. Schlesinger PH, Gross A, Yin XM, Yamamoto K, Saito M, Waksman G et al Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 1997; 94: 11357-11362.
4. Cheng EH-YA, Wei MC, Weiler S, Flavell RA, Mak TM, Lindsten T et al BCL-2, BCL-xL sequester BH3 domain-only molecules preventing BAX and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705-711.
5. Verma IM, Stevenson JK, Scharz EM, van Antwerp DV, Miyamoto S. Rel/ NF-κB/IκB family: Intimate tails of association and dissociation. Genes Dev 1995; 9: 2723-2735.
6. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-kappaB activity. Annu Rev Immunol 2000; 18: 621-623.
7. Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, Reed JC et al. Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines. Oncogene 2001; 20: 2805-2813.
8. Grimm T, Scheider S, Naschberger E, Huber J, Guenzi E, Keiser A et al EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005; 105: 3263-3269.
9. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/ p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000; 113: 1661-1670.
10. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
11. Kaeser MD, Iggo RD. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 2002; 99: 95-100.
12. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998: 188: 1763-1768.
13. De Laurenzi V, Catani MV, Terrinoni A, Corazzari M, Melino G, Costanzo A et al. Additional complexity in p73: Induction by mitogens in lymphoid cells and identification of two splicing variants epsilon and zeta. Cell Death Differ 1999: 6: 389-390.
14. Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SE. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 2000: 407: 642-645.
15. Wan YY, DeGregori J. The survival of antigen-stimulated T cells requires NF-KB-mediated inhibition of p73 expression. Immunity 2003; 18 331-342.
16. Marinari B, Costanzo A, Marzano V, Piccolella E, Tuosto L. CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 nuclear factor-kappaB subunits on IL-8 and Bcl-xL gene promoters. Proc Natl Acad Sci USA 2004; 101: 6098-6103.
17. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M et al The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-809.
18. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to -DNA damage. Nature 1999; 399: 814-817.
19. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 605-615.
20. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol Cell 2004; 13: 853-865.
21. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004; 24: 1007-1021.
22. Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR et al Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000; 191: 1721-1734.
23. Kane LP, Andres PG, Howland RG, Abbas AK, Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2001; 2: 37-44.
24. Rathmell JC, Lindsten T, Zong W-X, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3: 932-939.
25. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausser Lechner MJ et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003; 302: 1036-1038.
26. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
27. Senoo M, Manis JP, Alt FW, McKeon F. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 2004; 6: 85-89.
28. + lymphocytes. J Immunol 2000; 165: 1743-1754.
29. Strasser A, Harris AW, Huangh DC, Krammer PH, Cory S. Bcl-2 and Fas/ APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14: 6136-6147.
30. Van Parijs L, Peterson DA, Abbas AK. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998; 8: 265-274.
31. Burkhart BA, Hebbar PB, Trotter KM, Archer TK. Chromatin-dependent E1A activity modulates NF-kappaB RelA-mediated repression of glucocorticoid receptor-dependent transcription. J Biol Chem 2005; 25: 6349-6358.
32. Chao DT, Korsemeyer SJ. Bcl-xL-regulated apoptosis in t cell development. Int Immunol 1997; 9: 1375-1384.
33. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002; 277: 14040-14047.
34. Basu S, Totty NF, Irwin M, Sudol M, Downward J. Akt phosphorylate the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23.
35. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell 2005; 18: 447-449.
36. Piccolella E, Spadaro F, Ramoni C, Marinari B, Costanzo A, Levrero M et al. Vav-1 and the IKKα subunit of IκB kinase (IKK) functionally associate to induce nuclear factor-κB activation in response to CD28 engagement. J Immunol 2003; 170: 2895-2903.